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The study of the reactivity of the novel pyrazole derivative [1-{MeOe(CH2)2e}-3,5-Ph2e(C3HN2)] (1) 41 
with Na2[PdCl4] or Pd(OAc)2 under different experimental conditions has allowed us to isolate and 42 
characterize the trans-isomers of [Pd{[1-{MeOe(CH2)2e}-3,5-Ph2e(C3HN2)]}2(X)2] [X = Cl (2) or 43 
OAc (3)] and the di-m-ligand bridged cyclopalladated complexes [Pd{k2,C,N[1-{MeOe(CH2)2e}-3-44 
(C6H4),5-Ph-(C3HN2)]}(m-X)]2 [X = OAc (4) or Cl (5)]. Further treatment of compounds 4 or 5 with 45 
PPh3 in CH2Cl2 produced the bridge splitting and the formation of [Pd{k2,C,N[1-{MeOe(CH2)2e}-3-46 
(C6H4),5-Ph-(C3HN2)]}X(PPh3)] [X = OAc (6) or Cl (7)]. The cytotoxic assessment of the free ligand 47 
(1) and the Pd(II) complexes on the two breast cancer cell lines MCF7 and MDA-MB231 reveals that: 48 
a) compound 1 is less active than its analogue [1-{Me2Ne(CH2)2e}-3,5-Ph2e(C3HN2)] (Ic) and b) 49 
palladacycles 4e7 showed a remarkable cytotoxic activity in the MDA-MB231 cell line (with IC50 50 








Pyrazoles are widely used as core motifs for a large number of compounds of significant relevancy and 57 
they have a variety of applications (i.e. as agrochemicals, dyes, food additives, catalysts and 58 
pharmaceuticals) [1e2]. Moreover, N-substituted derivatives are particularly attractive in view of their 59 
antiproliferative properties against cancer cells [3,4]. Furthermore, this type of heterocycles have a rich 60 
and versatile coordination ability with transition metals that affects their properties [5e6]. This fact, 61 
together with the increasing interest in the design of novel antitumoral drugs with greater efficiency, 62 
lower toxicity and less undesirable side effects than the current Pt-based drugs [7], have triggered the 63 
development of novel Pd(II) and Pt(II)-pyrazole containing complexes [8e13]. Substituted pyrazoles in 64 
which there is a s(CeH) bond with the proper orientation are valuable substrates to achieve cyclopallada- 65 
or platinated complexes [11e13]. This sort of metallacycles are relevant due to their chemical, physical 66 
or optical properties and their applications in different areas (i.e. as precursors in organic, organometallic 67 
synthesis, homogeneous catalysis and as building blocks in supramolecular chemistry) [14,15]. 68 
On the other hand, bioorganometallic chemistry is a rapid developing area of increasing interest and the 69 
idea of using organometallic complexes in drug discovery is becoming more and more popular [16,17]. 70 
Antimalarials, antibacterials, neuroprotectors, based on organometallic compounds have been described 71 
[16,17]. Moreover, recent contributions suggest that cyclopallada- and cycloplatinated compounds are 72 
probably amongst the best candidates for the design of newanticancer drugs [18e20]. 73 
Despite the increasing interest in both Pd(II)-pyrazole complexes [21,22] and cyclometallated 74 
compounds [14,15,18e20], only a few articles on cyclopalladated-pyrazole derivatives have been 75 
published [11,13]. We have recently reported three N-substituted pyrazoles of general formulae 1-76 
{Me2Ne(CH2)2e}-3,5-R2e(C3HN2) (I) (Fig. 1), their Pd(II) and Pt(II) complexes of general formulae 77 
([M {1-[Me2Ne(CH2)2e]-3,5-R2-(C3HN2)}Cl2] [(II) and (III), in Fig. 1) and the cyclometallated 78 
derivatives (IV and V) [11b]. The comparison of their antitumoral activity in three different cell lines 79 
(MDAMB231, MCF7 and A549) revealed that: a) pyrazoles (I) with R = Ph were more potent than their 80 
analogues with R = H or Me, b) the binding of these ligands to Pd(II) or Pt(II) produced an enhancement 81 
of their activity, and c) cyclometallated products (IV and V) were more potent than complexes IIc and 82 
IIIc in which the pyrazole Ic acts as a bidentate (N,N0) ligand. 83 
In view of these findings and in order to elucidate the effect produced by the functional group on the 84 
pendant arm of the heterocyclic nitrogen, now we report a parallel study on the novel pyrazole: [1-85 
{MeOe(CH2)2e}-3,5-Ph2e(C3HN2)] (1), that has the OMe group attached at the end of the e(CH2)2e 86 








Materials and methods 93 
 94 
All the reagents were obtained from commercial sources and used as received. Solvents were distilled 95 
and dried before use [23]. Elemental analyses were carried out at the Serveis Científico-Tècnics 96 
(Universitat Barcelona). Mass spectra (ESIþ) were performed at the Servei d’Espectrometria de Masses 97 
(Universitat de Barcelona). Infrared (IR) spectra were obtained with a Nicolet 400FTIR instrument using 98 
KBr pellets. A selection of the most relevant absorptions observed in the IR spectra are presented in the 99 
following sections. Ultravioletevisible (UVevis) spectra of CH2Cl2 solutions of the free ligand 1 and 100 
the Pd(II) compounds (5e7) were recorded at 298 K with a Cary 100 scan 388 Varian UV spectrometer. 101 
Thewavelengths (l, in nm) and the extinction coefficients (ε, in M-1 cm-1) of the bands observed in the 102 
UVevis spectra are specified in the characterization section of the corresponding product. The retention 103 
coefficients (Rf) were obtained using SiO2 (Merck silica gel 60 F254) plates. High resolution 1H NMR 104 
spectra and the two-dimensional [{1He1H} NOESY and COSY and {1He13C}-heteronuclear single 105 
quantum coherence (HSQC), and heteronuclear multiple bond coherence (HMBC)] experiments were 106 
registered with a Varian VRX-500 or a Bruker Avance DMX-500 MHz instruments. 13C{1H} NMR 107 
spectra and 31P{1H} spectra of compounds 6 and 7 obtained with a Mercury-400 and a Varian 300 108 
MHz instrument, respectively. NMR studies of 1e3 and 5e7 were carried out at 298 K, using CDCl3 109 
(99.9%) as solvent and SiMe4 [for 1H and 13C{1H} NMR] and P(OMe)3 [d(31P) = 140.17 ppm for 110 
31P NMR] as references. Due to the low solubility of complex 5 in CDCl3 its NMR studies were 111 
performed in DMSO-d6 (99.8%). In all cases, chemical shifts (d) are given in ppm and the coupling 112 
constants (J) in Hz. In the characterization section of each product the assignment of signals detected in 113 
their NMR spectra refers to the labelling patterns presented in Scheme 1 (Abbreviations for the 114 
multiplicities of the signals observed in the NMR spectra: s = singlet, d = doublet, t = triplet, m = 115 




Preparation of 1-{MeOe(CH2)2e}-3,5-Ph2e(C3HN2) (1)  120 
Potassium hydroxide (0.800 g, 14 x 10-3 mol) was treated with 9.0 mL of DMSO and the resulting 121 
mixturewas magnetically stirred at room temperature (ca. 298 K) for 30 min. After this period 3,5-122 
diphenylpyrazole (0.788 g, 3.58 x 10-3 mol) was added and the stirring was maintained for 30 min at 123 
298 K. Then, 1-chloro 2-methoxyethane (4.0 mL, 45 x 10-3 mol) was gradually added and the reaction 124 
mixture was left overnight under stirring at 298 K. After this period, 50 mL of iced cold water was added 125 
to eliminate the unreacted KOH; the organic phase was then extracted with diethylether and washed 126 
repeatedly with water, dried over Na2SO4 and filtered. Then, the filtrate was concentrated to dryness 127 
on a rotary evaporator. The solid formedwas collected and later on dried in vacuum for 3 days. [Yield: 128 
0.880 g, (88%)]. Characterization data: Anal (%). Calc. for C18H18N2O (MW = 278.35): C, 77.67; H, 129 
6.52; N, 10.06%; found: C, 77.8; H, 6.6 and N, 10.1. MS (ESIþ): m/z = 279.15 {[M] þ H}þ. IR selected 130 
data: 3059e3015 [n(CeH)] and 2987e2952 [n(CeH)], 1481(m), 1462(s), 1441(m), 1363(m), 1300(m), 131 
1115(s), 1012(m), 762(s), 691(s) cm-1. UVevis data (c = 5.74 x 10-5 M in CH2Cl2): l (ε) = 223 (1.5 x 132 
104) and 253 (3.1 x 104). Rf (in CHCl3) = 0.24. 1H NMR data: d = 3.32 (s, 3H, OMe); 3.91 [t, 3JH,H 133 
= 7.2, 2H, (eCH2ed)]; 4.34 [t, 3JH,H = 7.2, 2H, (eCH2ec)]; 6.65 (s, 1H, H4); 7.35 (t, 3JH,H = 7.7, 1H, 134 
H4b); 7.47e7.60 (m, 5H, H3a, H4a, H5a, H3b and H5b); 7.70 (d, 2H, 3JH,H = 7.6, H2b and H6b), 7.92 135 
(d, 2H, 3JH,H = 7.5, H2a and H6a). 13C{1H} NMR data: 49.1 (Cd); 58.9 (OMe); 71.4 (Cc); 103.4 (C4); 136 
5 
 
125.3 (C2b and C6b); 125.7 (C2a and C6a); 126.0 (C4b); 126.8 (C4a); 128.7 (C3a and C5a); 129.2 (C3b 137 
and C5b); 130.7 (C1b); 133.6 (C1a); 145.9 (C5) and 150.9 (C3). 138 
 139 
Preparation of trans-[Pd{[1-{MeOe(CH2)2e}-3,5-Ph2e (C3HN2)]2Cl2] (2) 140 
To a solution formed by Na2[PdCl4] (100 mg, 3.4 x10-4 mol) and methanol (10 mL), ligand 1 (189 mg, 141 
6.8 x 10-4 mol)was added and the reaction mixture was stirred at 298 K for 2 h. The yellow solid formed 142 
was filtered and dried overnight. Afterwards, it was dissolved in the minimum amount of CH2Cl2 and 143 
passed through a SiO2 (2.0 cm x 8.0 cm) column. Elution with CH2Cl2 produced a wide yellow band 144 
which was collected and concentrated to dryness on a rotary evaporator and the bright yellow solid 145 
formed was collected and finally dried in vacuum for 2 days [Yield: 196 mg (78%)]. Characterization 146 
data: Anal. (%) Calc for C36H36Cl2N4O2Pd: (MW = 734.0): C, 58.91; H, 4.94; N, 7.63; Found: C, 147 
59.0; H, 5.0; N, 7.5. MS (ESIþ): m/z = 697.16 {[M] - Cl}+. IR selected data: 3047e 3015 [n(CeH)] and 148 
2980e2925 [n(CeH)], 1483(m), 1461(m), 1448(m), 1124(s), 765(s) and 700(s) cm-1. UVevis data: (c = 149 
8.17 x 10-6 M in CH2Cl2): l (ε) = 238 (3.8 x 105), broad band. Rf (in CHCl3) = 0.19. 1H NMR data: d 150 
= 3.20 [s, 6H, 2 (OMe)]; 3.96 [t, 3JH,H = 6.9, 4H, 2 (eCH2-d)]; 4.89 [t, 3JH,H = 6.9, 4H, 2 (eCH2ec)]; 151 
6.36 [s, 2H, 2 (H4)]; 7.40e7.58 [br. m, 12H, 2(H3a, H4a, H5a, H3b, H4a and H5b)]; 7.62 [d. 3JH,H = 152 
7.6, 4H, 2 (H2b and H6b)] and 8.20 [d, 3JH,H = 7.6, 4H, 2 (H2a and H6a)]. 13C{1H} NMR data: 50.31 153 
(2 Cd); 58.7 (2 OMe); 69.9 (2 Cc); 108.5 (2C4); 125.5 [2 (C2b and C6b)]; 125.9 (2C4b); 126.4 (2C4a); 154 
128.5 [2 (C2a and C6a)]; 129.4 (2C1b), 129.8 [2 (C3b and C5b)]; 130.1 [2 (C3a and C5a)]; 132.7 (2C1a); 155 
149.7 (2C5) and 154.7 (2C3). 156 
 157 
Preparation of trans-[Pd{[1-{MeOe(CH2)2e}-3,5-Ph2e (C3HN2)]2(OAc)2] (3) and [Pd{k2,C,N)[1-158 
{MeO-(CH2)2}-3-(C6H4),5-Ph-(C3HN2)]}(m-OAc)]2 (4) 159 
76 mg (3.4 x 10-4 mol) of Pd(OAc)2 was dissolved in 15 mL of toluene at 298 K, then ligand 1 (95 mg, 160 
3.4 x 10-4 mol) was added. The reaction flask was protected from the light with aluminium foil and 161 
refluxed for 12 h. After this period the black solution was concentrated to dryness on a rotary evaporator 162 
and left overnight in a dessicator. The residue was then treated with CH2Cl2 (15 mL) and passed through 163 
a Celite pad to remove the metallic palladium. This was repeated until colourless mother liquors were 164 
obtained. The solutionwas dried with Na2SO4 and the filtratewas concentrated to dryness on a rotary 165 
evaporator. The brownish solid formed consisted on a mixture of compounds 3 and 4 in a molar ratio 166 
(3:4 = 1:10). These products were isolated by SiO2 column chromatography. Elution with CHCl3 167 
produced a pale yellow band that gave after concentration 11 mg of the minor product (3). Afterwards 168 
the use of a CHCl3:MeOH (100:0.4) mixture released another band that was collected and concentrated 169 
to dryness on a rotary evaporator. The yellowish solid formed (4) was collected, air-dried and dried in 170 
vacuum for 2 days (yield: 112 mg). Characterization data for 3: Anal. (%) Calc. for C40H42N4O6Pd 171 
(MW = 780.21): C, 61.59; H, 5.4; N, 7.17; Found: C, 61.4; H, 5.5; N, 7.0. MS (ESIþ): m/z = 721.2 {[M] 172 
- (OAc)}+. IR selected data: 3067e3023 [n(CeH)] and 2984e 2940 [n(CeH)], 1566 [nas(COO)] and 1386 173 
[ns (COO)] cm-1. UVe vis data: (c = 1.43 x10-5 M in CH2Cl2): l (ε) = 234 (4.1 x105) broad band. Rf 174 
(in CHCl3) = 0.21. 1H NMR data: d = 1.83 [br. s, 6H, 2 (OAc)]; 3.15 (s, 6H, 2 OMe); 3.95 [t, 3JH,H = 175 
7.1, 4H, 2 (eCH2ed)]; 4.75 [t, 3JH,H = 7.1, 4H, 2 (eCH2ec)]; 6.40 (s, 2H, 2H4); 7.37e7.58 [m, 16H, 176 
2(H3a, H4a, H5a, H2b, H3b, H4b, H5b and H6b)] and 8.16 [d, 3JH,H = 7.6, 4H, 2 (H2a and H6a)]. 177 
13C{1H} NMR data: 23.3 [2Me(OAc)]; 50.2 (2Cd); 58.4 (2OMe); 70.1 (2Cc); 108.7 (2C4); 125.7 178 
[2(C2b and C6b)]; 126.1 (2C4b); 126.4 (2C4a); 128.6 [2(C2a and C6a)]; 129.5 [2(C3b and C5b)]; 130.0 179 
[2(C3a and C5a)]; 130.4 (2C1b); 132.6 (2C1a); 149.5 (2C5); 154.3 (2C3) and 180.9 [2 > COO(OAc)]. 180 
For 4: Anal. (%) Calc. for C40H40N4O6Pd2 (MW = 886.1): C, 54.25; H, 4.55; N, 6.32; Found: C, 54.1; 181 
H, 4.5; N, 6.0. MS (ESIþ): m/z = 425.06 {[M] - 2(OAc) þ 2(CH3CN)}2þ/2. IR selected data: 3060e3018 182 
[n(Ce H)] and 2984e2940 [n(CeH)], 1560 [nas(COO)] and 1413 [ns(COO)] cm-1. UVevis data: (c = 183 
6 
 
1.91 x 10-5 M in CH2Cl2): l (ε) = 223 (3.2 x 105), 247 (2.5 x 105) and 341(broad, z1.9 x 103). Rf (in 184 
CHCl3) = 0.14. 1H NMR data: d = 2.01 [br. s, 6H, 2(OAc)]; 3.17 [s, 6H, 2(OMe)]; 3.30e3.40 [(br. m, 185 
4H, 2(eCH2ed)]; 3.67 [m, 2H, 2 (one of the two protons of the eCH2ec unit)]; 3.93 [m, 2H, 2 (the other 186 
proton of the eCH2ec unit)]; 6.04 [s, 2H, 2(H4)]; 6.74 [m, 2H, 2(H3a)]; 6.81 [m, 2H, 2(H4a)]; 7.31e7.80 187 
[m, 10H, 2(H5a, H6a, H3b, H4b and H5b)] and 8.51 [br., 4H, 2(H2b and H6b)]. 13C{1H} NMR data: 188 
23.9 [2Me(OAc)]; 49.7 (2Cd); 58.2 (2OMe); 70.6 (2Cc); 109.3 (2C4); 125.5 [2 (C2b and C6b)]; 125.9 189 
(2C4b); 126.3 (2C4a); 127.6 (2C5a); 128.3 (2C6a); 129.0 [2 (C3b and C5b)]; 129.7 (2C3a); 130.2 190 
(2C1b); 132.3 (2C1a); 148.9 (2C2a), 150.6 (2C5); 153.9 (2C3) and 178.9 [2 > COO (OAc)]. 191 
 192 
Preparation of [Pd{k2,C,N)[1-{MeOe(CH2)2}-3-(C6H4),5-Phe (C3HN2)]}(m-Cl)]2 (5) 193 
Compound [Pd{k2,C,N[1-{MeOe(CH2)2}-3-(C6H4),5-Phe (C3HN2)]}(m-OAc)]2 (4) (40 mg, 4.37 x 194 
10-5 mol) was suspended in acetone (20 mL), then LiCl (5 mg, 1.1 x 10-4 mol) was added. The resulting 195 
mixture was stirred overnight at 298 K. The solid formed was collected by filtration and dried in vacuum 196 
for 2 days [Yield: 32 mg, (81%)]. Characterization data: Anal. (%) Calc. for C36H34Cl2N4O2Pd2 (MW 197 
= 838.43): C, 51.7; H, 4.09; N, 6.68; Found: C, 51.6; H, 4.2; N, 6.8. MS (ESIþ): m/z = 383.761 {[M] - 198 
2Cl}2þ/2. IR selected data: 3055e3022 [n(CeH)] and 2988e2924 [n(CeH)]. UVe vis data: (c = 1.91 x10-199 
5 Min CH2Cl2): l (ε) = 240 (br. 2.5 x105) and 338 (z3.6 x 103). 1H NMR data (in DMSO-d6): d = 3.22 200 
[s, 6H, 2(OMe)]; 3.30 [br. m, 2H, {one of the protons of the (eCH2ed) unit}], 4.03 [m, 2H, 2 {one of 201 
the protons of the (eCH2ec) moiety]; the signals due the remaining protons the (eCH2e)c and d moieties 202 
were masked by the broad signal (at d = 3.50 ppm) of the residual water present in the DMSO-d6, their 203 
chemical shifts [ca. 3.45 (e CH2ed) and 3.85 for that of the eCH2ec unit] were obtained from the HSQC 204 
experiment; 6.07 [s, 2H, 2(H4)]; 6.74 [m, 2H, 2(H3a)]; 6.81 [m, 2H, 2(H4a)] and 7.18e8.10 [br. m, 14H, 205 
2(H5a, H6a, H2b, H3b, H4b, H5b and H6b)]. 13C{1H} NMR data (in DMSO-d6): 50.1 (2Cd); 58.0 206 
(2OMe); 70.3 (2Cc); 109.1 (2C4); 125.0 [2(C2b and C6b)]; 125.7 (2C4b); 126.0 (2C4a); 127.9 (2C5a); 207 
128.4 (2C6a); 128.9 [2(C3b and C5b)]; 129.6 (2C3a); 130.4 (2C1b); 131.8 (2C1a); 151.2 (2C5); 152.0 208 
(2C2a) and 153.7 (2C3)]. 209 
 210 
Preparation of [Pd{k2,C,N)[1-{MeOe(CH2)2e}-3-(C6H4),5-Phe (C3HN2)]}(X)(PPh3)] {X = OAc (6) 211 
or Cl (7)} 212 
To a mixture containing 3.8 x 10-5 mol of the corresponding dimeric complex 4 (35 mg) {or 5 (34 mg)} 213 
and 20 mL of CH2Cl2, PPh3 (20 mg, 7.6 x 10-5 mol) was added. The resulting mixturewas kept under 214 
stirring for 20 min and then filtered. The pale yellowish filtrate was concentrated to dryness on a rotary 215 
evaporator and the solid formed was collected, air-dried and recrystallized in a CH2Cl2:n-hexane (1:1) 216 
mixture [Yields: 38 mg (70%) and 40 mg (77%) for 6 and 7, respectively]. Characterization data for 6: 217 
Anal. Calc for C38H35N2O3PPd (MW = 705.9): C, 64.73; H, 5.00; N, 3.97%; Found: C, 64.6; H, 5.1 218 
and N, 4.0; MS (ESIþ): m/z = 645.14 {[M] (OAc)}þ. IR selected data: 3050e3018 [n(CeH)] and 2985e 219 
2925 [n(CeH)]; 1590 [nas(COO)] and 1381 [ns(COO)] and 1094 (PPh3, X-sensitive), cm-1. UVevis (c 220 
= 1.42 x 10-5 M in CH2Cl2): l (ε) = 229 (4.0 x 10-5), 246 (3.0 x 10-4) and 348 (3.5 x 10-3). Rf (in 221 
CHCl3) = 0.20. 1H NMR data: d = 1.85 (s, 3H, OAc); 3.12 (s, 3H, OMe); 3.67 (t, 3JH,H = 7.3, 2H, 222 
eCH2ed); 4.37 (t, 2H, 3JH,H = 7.0, eCH2ec); 6.07 (s, 1H, H4); 6.44 (br. 1H, H3a); 6.96 (m, 1H, H4a); 223 
7.28e7.96 [br. m, 22H, (H5a , H6a, H2b-H6b, and aromatic protons of the PPh3 ligand)]. 13C{1H} 224 
NMR data: 23.3 [Me(OAc)], 51.4 (Cd); 58.5 (OMe); 70.2 (Cc); 110.2 (C4); 125.3 (C4b); 126.5 (C4a); 225 
127.4 (C2b and C6b); 128.0 (C6a); 128.4 (C5a); 129.1 (C3b and C5b); 129.5 (C3a); 129.8 (C1b); 132.5 226 
(C1a); 150.2 (C5); 151.2 (C2a); 154.7 (C3), 180.4 [>COO(OAc)] and four additional doublets due to 227 
four types of carbon-13 nuclei (ipso, ortho, meta and para) of the PPh3 ligand. 31P{1H} NMR data: d 228 
= 40.3. For 7: Anal. Calc. for C36H32ClN2OPPd (MW = 680.1): C, 63.45; H, 4.73; N, 4.11%; Found: 229 
C, 63.2; H, 4.8; N, 4.1; MS (ESIþ): m/z = 645.14 {[M] - Cl}þ. IR selected data: 3049e3018 [n(CeH)] 230 
7 
 
and 2982e2925 [n(CeH)] and 1094 (X-sensitive of the phosphine ligand) cm-1. UVevis data: (c = 1.8 x 231 
10-5 M in CH2Cl2): l (ε) = 242 (2.0 x 10-5); and 341 (3.9 x 10-3). 1H NMR data: d = 3.11 (s, 3H, OMe); 232 
3.82 (br., 2H, eCH2ed); 4.50 (br., 2H, eCH2ec); 6.35 (s, 1H, H4); 6.58 (m, 1H, H4a); 6.84 (m, 1H, H3a) 233 
and 7.30e8.10 [br. m, 22H, (H5a, H6a, H2b-H6b and aromatic protons of the PPh3 ligand)]. 13C {1H} 234 
NMR data: 51.2 (Cd); 58.4 (OMe); 70.1 (Cc); 110.1 (C4); 125.4 (C4b); 126.3 (C4a); 127.3 (C2b and 235 
C6b); 127.8 (C6a); 128.6 (C5a); 129.0 [(C3b and C5b); the {1He13C}-HSQC spectra showed that the 236 
signal due to C3a was overlapped by this one]; 129.6 (C1b); 132.8 (C1a); 149.9 (C5); 152.6 (C2a); 153.8 237 





A plaque-like specimen of compound 2 (dimensions in Table 1), was used for the X-ray crystallographic 243 
analysis. The X-ray intensity data were measured and integration of the data using a triclinic unit cell 244 
yielded a total of 11,383 reflections to a maximum q angle of 28.34° (0.75 Å resolution), of which 4182 245 
were independent (average redundancy 2.722, completeness = 99.7%, Rint = 2.43%, Rsig = 2.81%) and 246 
3912 (93.54%) were greater than 2s(F2). The final cell constants (Table 1) are based upon the refinement 247 
of the XYZcentroids of reflections above 20 s(I). 248 
 249 
The structure was solved and refined using the Bruker SHELXTL Software Package, [24] using the 250 
space group P-1, with Z = 1 for the formula unit, C36H36Cl2N4O2Pd. The final anisotropic full-matrix 251 
least-squares refinement on F2 with 205 variables converged at R1 = 3.10%, for the observed data and 252 
wR2 = 8.03% for all data. The goodness-of-fit was 1.055. The largest peak in the final difference 253 
electron density synthesis was 0.562 e-/Å3 and the largest hole was -0.269 e-/Å3 with an RMS deviation 254 
of 0.065 e-/Å3. Final details concerning the resolution and refinement of the crystal structure are 255 
presented in Table 1. 256 





Breast cancer MCF7 and MDA-MB231 cells (from European Collection of Cell Cultures, ECACC) 262 
were grown as a monolayer culture in minimum essential medium (DMEM with L-glutamine, without 263 
glucose and without sodium pyruvate) in the presence of 10% heat-inactivated fetal calf serum, 10 mM 264 
of D-glucose and 0.1% streptomycin/penicillin in standard culture conditions. 265 
 266 
Cell viability assays 267 
For these studies, compounds were dissolved in 100% DMSO at 50 mM as stock solution; then, serial 268 
dilutions have been done in DMSO (1:1) (in this way DMSO concentration in cell media was always 269 
the same); finally, 1:500 dilutions of the serial dilutions of compounds on cell media were done. The 270 
assay was performed as described by Givens et al. [25]. In brief, MDA-MB231 and MCF7 cells were 271 
plated at 5000 cells/well or 10,000 cells/well respectively, in 100 mL media in tissue culture 96 well 272 
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plates (Cultek). After 24 h, media was replaced by 100 mL/well of serial dilution of drugs. Each point 273 
concentration was run in triplicate. Reagent blanks, containing media plus colorimetric reagent without 274 
cells were run on each plate. Blank values were subtracted from test values and were routinely 5e10% 275 
of uninhibited control values. Plates were incubated for 72 h. Hexosamidase activity was measured 276 
according to the following protocol: the media containing the cells was removed and cells werewashed 277 
once with PBS 60 mL of substrate solution (pnitrophenol-N-acetyl-b-D-glucosamide 7.5 mM [Sigma 278 
N-9376], sodium citrate 0.1 M, pH = 5.0, 0.25% Triton X-100) was added to each well and incubated at 279 
37 °C for 1e2 h; after this incubation time, a bright yellow colour appeared; then, plates could be 280 
developed by adding 90 mL of developer solution (Glycine 50 mM, pH = 10.4; EDTA 5 mM), and 281 




Results and discussion 284 
 285 
Synthesis 286 
Compound 1-{MeOe(CH2)2e}-3,5-Ph2e(C3HN2) (1) was obtained in a fairly good yield (88%) by 287 
alkylation of 3,5-diphenylpyrazole with a three-fold excess of 1-chloro 2-methoxyethane [Scheme 1, 288 
step (i)] [26]. Treatment of 1-{MeOe(CH2)2e}-3,5-Ph2e(C3HN2) (1) with Na2[PdCl4] (in a 1:1 or 289 
2:1Mratio) in methanol at 298 K produced a yellow solid that was identified as [Pd{[1-290 
{MeOe(CH2)2e}-3,5-Ph2e(C3HN2)]}2Cl2] (2) [Scheme 1, step (ii)]. Its X-ray crystal structure (see 291 
below) confirmed that it was the trans isomer. Whenligand 1was reacted with Pd(OAc)2 in toluene under 292 
reflux for 12 h a black solution was obtained. The subsequent chromatography on silica gel gave two 293 
products 3 and 4 [Scheme 1, step (iii)] in a molar ratio 4:3 =10:1. The minor component (3) was 294 
identified as trans-[Pd{[1-{MeOe(CH2)2e}-3,5-Ph2e(C3HN2)]}2(OAc)2] and characterization data of 295 
the major product (4) were consistent with those expected for the di-m-acetato-bridged cyclopalladated 296 
complex [Pd{k2,C,N[1-{MeOe(CH2)2e}-3-(C6H4),5-Phe(C3HN2)]}(m-OAc)]2 that arises form the 297 
activation of the s(CeH) bond of the phenyl ring in position 3 of the pyrazole. The reaction of 4 with an 298 
excess of LiCl in acetone at 298 K gave the dinuclear compound [Pd{k2,C,N[1-{MeOe(CH2)2e}-3-299 
(C6H4),5-Phe(C3HN2)]}(m-Cl)]2 (5) as a pale brownish solid [Scheme 1, step (iv)]. Further treatment 300 
of di-m-ligand bridged cyclopalladated products (4 or 5) with PPh3 (in a 1:2 M ratio) in CH2Cl2 301 
produced the splitting of the “Pd(m-X)2Pd” units and the formation of the monomeric derivatives 302 
[Pd{k2,C,N)[1-{MeOe(CH2)2e}-3-(C6H4),5-Phe(C3HN2)]}(X)(PPh3)] with X = OAc (6) or Cl (7) 303 
[Scheme 1, step (v)] respectively. 304 
 305 
Characterization 306 
The new ligand (1) and its palladium(II) derivatives (2e7) were characterized by elemental analyses, 307 
mass spectra and infrared spectroscopy. In all cases the elemental analyses were consistent with the 308 
proposed formulae. 309 
The IR spectra of the complexes 3, 4 and 6 showed the typical bands due to the symmetric and 310 
asymmetric stretchings of the e COO- unit [27] and the separation between them was consistent with 311 
the values reported for related Pd(II)-compounds containing OAc- ligands acting as monodentate group 312 
(in 3 and 6) or as a bridging ligand (in 4) [27]. For compounds 6 and 7, with the PPh3 ligand, X-sensitive 313 
bands were also detected in their IR spectra. 314 
Compound 2 was also characterized by X-ray diffraction. Its molecular structure and the atom labelling 315 
scheme is presented in Fig. 2. The crystal contains molecules of [Pd{[1-{MeOe(CH2)2e }-3,5-316 
Ph2e(C3HN2)]2Cl2] in which, the Pd(II) atom is bound to two nitrogen atoms of two units of 2 and two 317 
chlorido ligands. Bond lengths and angles around the palladium(II) are similar to those reported for 318 
related trans-[Pd(L)2Cl2] complexes (with L = Nsubstituted pyrazoles) [28e30]. 319 
The Pd(II) atom is located on an inversion centre and as a consequence of this: a) the two Cl- ligands 320 
are in a transarrangement and b) the “(CH2)2OMe” pendant arms are on opposite sides of the 321 
coordination plane. In addition, “PdCl2” moiety is nearly orthogonal to the heterocycle and the phenyl 322 
rings are not coplanar with the pyrazolyl ring (angles between their main planes = 64.4 and. 36.0°). As 323 
a consequence of these arrangements the distance between the Cl- ligands and one of the protons of the 324 
eCH2eO00 unit [2.787 Å] is smaller than the sum or the van derWaals radii of these atoms [31]; thus 325 
suggesting an intramolecular CeH/Cl interaction [32]. 326 
In the crystal the molecules are assembled by CeH/p interactions (Fig. 3) involving: the centroids of the 327 
phenyl rings (Cg1 and Cg2) {defined by the sets of atoms [C1eC6] and [C10eC15], respectively} and 328 
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one of the hydrogen atoms of the OMe unit (H18C) and the H5 atom, [distances Cg1/H18C = 3.440 Å 329 
and Cg2/H5 = 3.477 Å].  330 
The new products were also characterized in solution by UVe vis spectroscopy and NMR. The 331 
absorption spectra of the new compounds were registered in CH2Cl2 at 298 K. The UVevis spectra of 332 
the Pd(II) complexes showed a band in the range 320 nm < l3 < 360 nm {not present in the spectrum of 333 
the free ligand (1)} with extinction coefficients between 2.0 x 103 and 4.0 x 103 M-1 cm-1. This band 334 
that has also been observed for related Pd(II) complexes with pyrazole ligands [11] is assigned to a 335 
metal-to-ligand charge transfer (MLCT) transition from the 4d orbitals of the Pd(II), to a p orbital of the 336 
ligand. The remaining bands detected at lower wavelengths (220 nm < l < 370 nm) are attributed to 337 
metal perturbed intraligand transitions (MPILT). 338 
In the 1H NMR spectra of the Pd(II) complexes (2e7), the chemical shifts of the OMe protons were very 339 
similar to that of the free ligand, thus suggesting that the oxygen of the methoxy group was not bound 340 
to the Pd(II) centre. NMR spectra of 3, 4 and 7 showed the typical resonances due to the OAc- ligand 341 
bound to the Pd(II) atom. The low-field region of these 1H NMR spectra was complex and the 342 
assignment of the signals detected was achieved with the aid of 2D NMR experiments [NOESY, COSY, 343 
{1He13C}-HSQC and HMBC]. 344 
For the palladacycles (4e7): a) the signal due to H2a proton was not observed in their 1H NMR spectra 345 
and b) the resonances of the H3a and H4a nuclei, appeared at higher fields than for the free ligand (1). 346 
Carbon-13 NMR and the 2D {1He13C}-HMBC spectra showed a downfield shift of the signal due to 347 
the metallated carbon (C2a). All these findings are consistent with previous NMR studies of 348 
cyclopalladated complexes [11a,14b,19b]. 349 
The 31P{1H}-NMR spectra of 6 and 7 showed a singlet at around 40 ppm. According to the bibliography 350 
[11], this is indicative of a cis-arrangement of the PPh3 ligand and the metallated carbon, in good 351 
agreement with the transphobia effect [33]. 352 
 353 
Study of the antitumor activity of the free ligand and the complexes 354 
The cytotoxic activity of the new ligand (1) and the palladium(II) complexes (2, 4e7) against two human 355 
breast cancer cell lines (MCF7 and MDA-MB231) was tested using cisplatin as positive control. The 356 
effects of these products on the growth of two cell lines were assessed after 72 h and the results are 357 
displayed in Fig. 4. The IC50 values corresponding to the inhibition of cancer cell growth at 50% level 358 
are listed in Table 2. For comparison purposes the IC50 parameters for the free ligand Ic and the 359 
palladacycle [Pd{k3,C,N,N0 [1-{Me2Ne(CH2)2e}-3,5-Ph2e(C3HN2)]2Cl] (V in Fig. 1) are also 360 
included [11b] (Fig. 5). 361 
The comparison of the in vitro cytotoxic activities of the free ligands (Ic and 1) against the MCF7 and 362 
MDA-MB231 cell lines shows (Table 2 and Fig. 4) that the presence of the NMe2 group on the pendant 363 
arm of the two 3,5-diphenyl pyrazole: [1-{R0e(CH2)2e }-3,5-Ph2e(C3HN2)] produces a greater 364 
cytotoxic effect than the OMe. This could be related to several factors such as their different lipophilicity 365 
and their proclivity to protonate in biological media [18,20]. 366 
Complex 2 did not show any significant effect on the MCF7 cell line. This result is similar to those 367 
obtained for compound: [Pd {k2,N,N0[1-{Me2Ne(CH2)2e}-3,5-Ph2e(C3HN2)]Cl2] (IIc shown in Fig. 368 
1). Except for 6, the remaining cyclopalladated complexes were more active in the MCF7 cell line than 369 
the free ligand (1) and compound 2. Among all these palladacycles, the di-m-acetatobridged complex 4 370 
was the most potent. Its effect was ca. 1.4 times greater than the palladacycle V (shown in Fig. 1) with 371 
a (C,N,N0)-pincer ligand [11b]. Unfortunately, none of these products exhibited IC50 values smaller 372 
than cisplatin.  373 
11 
 
More encouraging were the results obtained for MDAMB231 cell line. Compound 2 exhibited a 374 
moderate activity and for the remaining products, the IC50 values [in the range: 9.1 mM (for 6)e14.4 375 
mM (for 5)] were a bit smaller, if significant, than that of V [IC50 = 16.2 ± 4.6 mM] [11b] and closer to 376 
that of cisplatin [IC50 = 6.5 ± 2.4 mM]. Thus, suggesting that the new Pd(II) compounds were more 377 






The study of the reactivity of the novel N-substituted pyrazole derivative: [1-{MeOe(CH2)2e}-3,5-382 
Ph2e(C3HN2)] (1) with Na2[PdCl4] or Pd(OAc)2 has allowed us to isolate and characterize a family of 383 
palladium(II) complexes (2e7). In two of them (2 and 3) the Pd(II) atom is bound to the heterocyclic 384 
nitrogen. The remaining four complexes (4e7) contain one (in 6 and 7) or two (in 4 and 5) five-membered 385 
palladacycles formed by the binding of the same nitrogen and the metallation of the phenyl ring on 386 
position 3 of the pyrazole. These findings indicate that ligand 1 may adopt two binding modes [(N) or 387 
(C,N)-] in front of the Pd(II) atom. However, no evidences of the formation of complexes containing 1 388 
as a (C,N,O)- ligand were detected. 389 
The comparison of the results obtained from in vitro studies of their cytotoxic activity against the MCF7 390 
cell line and the MDAMB231 {triple negative (ER, PR and no HER2 over expression)} breast cancer 391 
cell line showed that the free ligand (1) was less active than its analogue Ic (Fig. 1) with the NMe2 unit 392 
at the end of the pendant arm. We have also proved that compounds (4e7) exhibit greater cytotoxic 393 
activity than the free ligand (1) and complex 2 (with two units of 1 acting as a monodentate N-donor 394 
ligand). The new cyclopalladated complexes (4e7) have an outstanding antiproliferative effect in the 395 
MDA-MB231 cell line. For all of them the IC50 values (Table 2) are a bit smaller than that reported for 396 
palladacycle V previously reported [11b]; but closer to that of cisplatin (under identical conditions). 397 
These results are especially outstanding because they open up new possibilities in the design of Pd(II)-398 
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Legends to figures  590 
 591 
Figure 1. General formulae of three N-substituted pyrazoles (I) and their Pd(II) and Pt(II) complexes 592 
recently reported [11b]. {In compounds IeIII, the R group represents H (a), Me (b) or Ph (c)}. 593 
 594 
Scheme 1. Key reagents and conditions: i) KOH, in DMSO, followed by treatment with 1-chloro 2-595 
methoxyethane, 298 K; ii) Na2[PdCl4] in MeOH at 298 K; iii) Pd(OAc)2 in refluxing toluene, (12 h), 596 
followed by SiO2 column chromatography; iv) LiCl in acetone, at 298 K; v) PPh3 in CH2Cl2 at 298 K. 597 
 598 
Figure 2. ORTEP plot of the molecular structure of trans-[Pd{[1-{MeOe(CH2)2e}-3,5-599 
Ph2e(C3HN2)]2Cl2] (2). Selected bond lengths (in Å) and angles (in deg.): Pd1eN1, 2.020(19); 600 
Pd1eCl1, 2.3044(5), N1eC9, 1.339(2); N1eN2, 1.362(2); N2eC7, 1.535(4); N2eC16, 1.460(3); C9eC10, 601 
1.472(3); C16eC17, 1.500(3); C17eO1, 1.404(3); O1eC18, 1.387(4); N1ePdeCl, 87.17(5); N1eN2eC16, 602 
120.98(16); N1eN2eC7, 110.24(16); N2e C7eC6,124.11(19); N2eC7eC8, 107.02(17); C7eC8eC9, 603 
106.76(18) and N1eC9eC10, 124.11(17). 604 
 605 
Figure 3. Schematic view of assembly of vicinal molecules of trans-[Pd{[1-{MeO-(CH2)2e }-3,5-606 
Ph2e(C3HN2)]2Cl2] (2) by C-Hꞏꞏꞏ interactions. Red balls represent the centroids of the rings defined 607 
by the sets of atoms [C1eC6] and [C10eC15] (Cg1 and Cg2, respectively). (For interpretation of the 608 
references to colour in this figure legend, the reader is referred to the web version of this article.) 609 
 610 
Figure 4. Inhibition of cell growth proliferation in MCF7 and MDA-MB231 human breast cancer cell 611 
lines, after 72 h of exposure to the free ligand 1 and compounds 2, 4e7. 612 
 613 
Figure 5. Comparative plot of the IC50 values (in mM) of the free ligands [1-{R’-(CH2)2e ]-3,5-614 
Ph2e(C3HN2)] {R’= NMe2 (Ic) or MeO (1)}, the Pd(II) complex trans-[Pd{[1-{MeOe(CH2)2e}-3,5-615 
Ph2e(C3HN2)]2Cl2] (2), the cyclopalladated compounds (4e7 and V) and cisplatin in front of the MCF7 616 





Table 1 Crystal data and structure refinement for trans-[Pd{[1-{MeOe(CH2)2e]-3,5-Ph2e 620 





Table 2 Cytotoxic activities (IC50 values) on MCF7 and MDA-MB231 cancer cell lines for ligands 1-624 
[R0e(CH2)2e]-3,5-Ph2e(C3HN2) with R0 = NMe2 (Ic) or OMe (1), the palladium(II) complex (2), the 625 
cyclometallated products (4e7 and V) and cisplatin under identical experimental conditions are also 626 
included. 627 
 628 
 629 
 630 
  631 
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